By Staff Reports
(DGIwire) – We don’t need to be scientists to know that medicine has made huge strides. In trauma care, major advances are usually associated with major wars. The anesthesia of the mid-19th century, for example, accompanied the Mexican-American War, and during the Vietnam War that technology was improved upon through the introduction of emergency response helicopters to the battlefield. Today, trauma response is at an all-time best. Highly trained, properly equipped technicians are often on the scene—whether on the battlefield or at the site of a car accident—in a matter of minutes. Responders are capable of dealing with almost any first-aid emergency thrown their way.
Despite the leaps and bounds made in emergency response care, trauma injuries are still a major threat. The National Trauma Center (NTC) paints a grim picture of the effects of trauma on the health and economic welfare of the American people. According to the NTC, trauma causes around 41 million emergency room visits and 2.3 million hospital admissions annually in the United States. Its most recent data show that in 2010, trauma was responsible for 180,811 deaths. In terms of what this means for the economy, trauma costs the U.S. nearly $406 billion annually between hospital bills and productivity lost to injury. Statistically, the cost of trauma is akin to fighting an entire war each year at home.
Still, it’s hard to see a way to cut down on traumatic injuries. Thousands of people every day get injured through unforeseen accidents, so beyond prevention, the only way to combat the human and economic costs of trauma is to improve the speed and efficacy of treatment.
To this end, Arch Therapeutics, a Wellesley, MA-based surgical device manufacturer, preparing for clinical trials with the AC5 Surgical Hemostatic Device™. AC5™ is a peptide-based medical product that might one day represent an efficient tool for addressing the ongoing crisis presented by traumatic injuries. AC5 is designed to speed up hemostasis, curtailing blood loss or other fluid leakage, allowing trauma professionals to treat wounds in a new way.
AC5 can be applied directly to a wound where it transforms into a physical barrier, stops the bleeding and allows doctors to operate on the exposed area. Since AC5 is clear and colorless, doctors should be able to see the wound area with less obstruction to their field of vision. In studies so far, AC5 has shown to be fast-acting and nontoxic, as well as absorbed naturally during the healing process.
Terrence W. Norchi, President and CEO of Arch Therapeutics, says, “Quick and effective trauma response is a major problem in the U.S. We believe AC5 has the potential to improve doctors’ ability to treat these injuries in a timely and efficient manner.”